Bispecific Radioligands (BRLs): Two Is Better Than One

Area of Science:

• Oncology
• Molecular Imaging
• Radiopharmaceuticals

Background:

• Tumor heterogeneity, encompassing genetic, epigenetic, and phenotypic variability, complicates cancer diagnosis and treatment.
• This cellular diversity can lead to differential responses to therapies, causing drug resistance and relapses.
• Tumor heterogeneity is dynamic, changing over time or in response to stimuli like treatment.

Purpose of the Study:

• To review the in vitro and in vivo studies of bispecific radioligands (BRLs) for molecular imaging in oncology.
• To assess the potential advantages of BRLs over traditional single-target radiopharmaceuticals in addressing tumor heterogeneity.

Main Methods:

• Review of in vitro and in vivo studies involving bispecific radioligands.
• Analysis of molecular imaging techniques for identifying tumor cell alterations.
• Assessment of radiopharmaceutical design, synthesis, and characterization.

Main Results:

• Bispecific radioligands (BRLs) with dual targeting capacity have emerged as a novel class of radiopharmaceuticals.
• These BRLs show potential in molecular imaging for oncology.
• Studies indicate BRLs may offer advantages over single-target agents.

Conclusions:

• Bispecific radioligands represent a promising advancement in molecular imaging for oncology.
• Their dual targeting capability may help overcome challenges posed by tumor heterogeneity.
• Further research and development of BRLs could enhance cancer diagnosis, prognosis, and personalized treatment strategies.